Drug recall · January 10, 2024
Eprontia recall
Why: Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1
- Lots / codes
Lot #: MB22020B, Exp 12/27/2023
- Quantity
- 2,220 bottles
- Company
- Azurity Pharmaceuticals, Inc., Wilmington, MA
- Distribution
- USA nationwide.
- Initiated
- December 8, 2023 · Voluntary: Firm initiated
- Classified
- January 2, 2024
- Reported
- January 10, 2024
- Ended
- April 24, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Eprontia
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.